Speeches by Craft.

“John, if I could turn now to wraparound care and NICE guidance on that, during our inquiry we have heard about the importance of wraparound care from those with lived experience and from myriad professionals. Do you have any insights you can share about where and the extent to which the standards are being met for qual…”

“What do you think is needed then? Is the regulation fine and sufficient in this space, or is there something different that needs to—”

“Are you confident that that data that you are able to collect from this method reflects the accurate situation on the ground?”

“Do you feel that there is a bit of a gap then that lots of people can fall through?”

“You do not currently collect data around where the extent of wraparound care is taking place?”

“Is there a gap, therefore, in the evidence base for this, as you are an evidence-led organisation?”

“I am trying to get to the heart of whether you see that guidance being implemented when it comes to the wraparound care side of it. We obviously have data on the use of prescribing, but not necessarily on that holistic side. It sounds like at the moment you do not have data on whether that guidance is being adhered to.”

“That would be helpful. Is there more that regulators could do in this space, and what would be needed from the Government to support that?”

“If you do not collect the data on it, where does responsibility lie for monitoring the quality of that wraparound care?”

“That would be helpful, thank you. Moving on to more data-related questions, is there any data that you can share around the extent of inappropriate prescribing, which has come up repeatedly?”

“Even if it is contraindicated for other health ramifications?”

“What can take place in this space to stop people either getting medications that have potential adverse effects on them, because it is contraindicated for other conditions they have, or that are inappropriate, or accessing drugs that are completely illegal and do goodness knows what?”

“Would you consider including a contraindication for use on GLP‑1s below a minimum BMI? It seems like what you were saying is that could push more people to go towards the black market rather than—”

“Would it be based on concerns being reported to regulators?”

“Is there a risk that if the UK online and offline markets are regulated people will then opt to go elsewhere? Does that cause concern for you?”

“The others have summed up basically what I would say. However, I think the work that we have done on the Committee has really shone a light on how we are on the precipice of quite a crisis regarding this issue. We can move the debate forward a bit by shining a light and seeing what comes up.”

“I thank the hon. Member for her chairship of the Health and Social Care Committee during this inquiry. As someone who has bipolar disorder, it was a really difficult experience to sit through at times, as I watched witness after witness after witness speak to what is very much my own experience. I have called myself lu…”

“It would be really helpful to have an illustrative example of that. Before I hand back to the Chair, I am trying to get to the heart of what bit of what health is supposed to provide it would be useful to have on a statutory footing. Is it about the commissioning of services? Is it about early intervention and what is …”

“Have you got an example of that?”

“Good morning. I would like to move on to what the proposed reforms in the schools White Paper might mean for that missing “H”. How confident are you? Do you think that the new tiered model proposed in the White Paper—universal, targeted, targeted plus and specialist—and the introduction of individual support plans that…”